Azione KH6 NEWAMSTERDAM PHARMA COMPANY N.V.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue NewAmsterdam Pharma Company N.V. Deutsche Boerse AG

Azioni

KH6

NL00150012L7

Tempo reale stimato Tradegate
Altri mercati azionari
 19:02:03 17/07/2024 		Variaz. 5gg Var. 1 gen.
17,25 EUR +0,88% Grafico intraday di NewAmsterdam Pharma Company N.V. -4,55% +71,43%
08/07 NewAmsterdam Pharma completa l'arruolamento nello studio clinico pivotale di Fase 3 TANDEM, che valuta la combinazione a dose fissa di Obicetrapib più Ezetimibe in pazienti con HeFH e/o ASCVD o fattori di rischio ASCVD CI
11/06 NewAmsterdam Pharma ottiene un altro brevetto statunitense che estende la protezione della proprietà intellettuale di obicetrapib fino a luglio 2043 MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
NewAmsterdam Pharma Completes Enrollment for Phase 3 Trial of Potential Cardiovascular Disease Treatment
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione NAMS
  4. Azione KH6
  5. Notizie NewAmsterdam Pharma Company N.V.
  6. Altre lingue